Articles

Regulatory reform, patient access, and supply chain security were 3 of the key themes showcased this week on PharmTech.com.

PharmTech Weekly Roundup—June 5, 2026

Tom Sellig, Adare Pharma Solutions, shares how the CDMO is positioning for growth amid US reshoring and oral dose innovation trends.

Tom Sellig on CDMO Innovation and US Manufacturing Growth

President and CEO, Klote Medical Research Advisors

At CPHI Americas, Molly Klote, Klote Medical Research Advisors, spoke about how the pharma industry faces tariff volatility and reshoring pressure. She warned FDA wants actionable supply chain plans, not slogans, with quality built in.

Molly Klote on Reshoring, Tariffs, and the Future of Pharma Supply Chains

At CPHI Americas, Delaware Gov. Matt Meyer argues domestic pharma manufacturing is a national security priority and positions Delaware as the ideal reshoring hub.

Delaware Governor Meyer on Drug Pricing, Reshoring, and National Security

Nicholas Richardson is vice president of clinical development at Precision for Medicine.

Nicholas Richardson, vice president of clinical development at Precision for Medicine, explains how important infrastructure is for radiopharmaceutical development. 

Patient Access to Radiopharmaceuticals, Part 2

This week's news and expert commentary shows that regulatory timelines are tightening, strategic capital is moving into new therapeutic categories, and long-standing operational gaps are demanding real solutions. 

PharmTech Weekly Roundup—May 29, 2026

PharmTech takes a look back at US and European regulatory news from the month of May 2026.

Regulatory Actions in May 2026

Videos

Sandra Coufal, Toragen, discusses her team's research targeting precancerous cervical cells, backed by a Gates Foundation grant and world-class advisors.

Inside the Expert Network Guiding TGN-S15 to Market

Sandra Coufal, Toragen, shares promising Phase I results showing dramatic HPV DNA reductions and tumor shrinkage, with Phase II set to confirm efficacy and safety.

TGN-S11 and Early Indicators of Drug Activity

Increased regulatory flexibility for rare diseases, a critical shift toward automated, data-driven manufacturing, and strategic acquisitions in genetic medicine were some of the highlights this week.

PharmTech Videos